Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of ...
Mar 26, 2012
0
0
Ticagrelor, a potent anti-platelet medication, was approved by the Food and Drug Administration in the summer of 2011 and is known to significantly reduce the risk of stroke, heart attack, vascular death and death overall ...
Mar 26, 2012
0
0
Percutaneous coronary intervention (PCI), also known as coronary angioplasty or angioplasty, is a procedure used to treat acute coronary syndromes. PCI involves opening a blocked blood vessel by threading and inflating a ...
Mar 24, 2012
0
0
(HealthDay) -- Aspirin works as well as Plavix in patients with blocked leg arteries, a new European study finds.
Feb 22, 2012
1
0
The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according ...
Feb 3, 2012
0
0
Patients who discontinued use of an antiplatelet agent such as clopidogrel prior to undergoing cardiac surgery to lower their bleeding risk and received intravenously the platelet inhibitor cangrelor achieved a higher rate ...
Jan 17, 2012
0
0
Allergies to Plavix, also know by its chemical name, Clopidogrel occur in about six percent of patients given the drug, vital for the prevention of life-threatening stent thrombosis after angioplasty and percutaneous coronary ...
Jan 16, 2012
0
0
A new study published Wednesday cast doubt on the usefulness of a genetic test for patients taking the anti-coagulant drug Plavix, calling into question last year's FDA warning about the blood thinner.
Dec 29, 2011
0
0
Although the U.S. Food and Drug Administration (FDA) has recommended that a certain type of genetic testing (for the genotype CYP2C19) be considered before prescribing the drug clopidogrel to identify individuals who may ...
Dec 27, 2011
0
0
Among patients with stable cardiovascular disease who have a genetic variation that diminishes the response to the antiplatelet drug clopidogrel, tripling the standard daily dosage of this medication resulted in improved ...
Nov 16, 2011
0
0
